These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 17882719)

  • 41. Mobilization, collection, and transplantation of peripheral blood hematopoietic progenitor cells in a patient with multiple myeloma and hemoglobin SC disease.
    Tormey CA; Snyder EL; Cooper DL
    Transfusion; 2008 Sep; 48(9):1930-3. PubMed ID: 18513256
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 43. No evidence of hematopoietic stem cell mobilization in patients submitted to hepatectomy or in patients with acute on chronic liver failure.
    Di Campli C; Piscaglia AC; Giuliante F; Rutella S; Bonanno G; Zocco MA; Ardito F; Nuzzo G; Mancuso S; Leone G; Gasbarrini G; Pola P; Gasbarrini A
    Transplant Proc; 2005; 37(6):2563-6. PubMed ID: 16182744
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Increased plasma EPO and MIP-1 alpha are associated with recruitment of vascular progenitors but not CD34(+) cells in autologous peripheral blood stem cell grafts.
    Labonté L; Li Y; Yang L; Gillingham A; Halpenny M; Giulivi A; Sills T; Evans K; Zanke B; Allan DS
    Exp Hematol; 2009 Jun; 37(6):673-8. PubMed ID: 19463769
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Posttransplant thrombopoiesis predicts survival in patients undergoing autologous hematopoietic progenitor cell transplantation.
    Ninan MJ; Flowers CR; Roback JD; Arellano ML; Waller EK
    Biol Blood Marrow Transplant; 2007 Aug; 13(8):895-904. PubMed ID: 17640593
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.
    Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R
    Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278
    [TBL] [Abstract][Full Text] [Related]  

  • 47. High CD8+ lymphocyte dose in the autograft predicts early absolute lymphocyte count recovery after peripheral hematopoietic stem cell transplantation.
    Atta EH; de Azevedo AM; Maiolino A; Coelho CJ; Sarcinelli SM; de Alvarenga Máximo C; Marra VL
    Am J Hematol; 2009 Jan; 84(1):21-8. PubMed ID: 19006229
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Autologous peripheral blood progenitor cells cryopreserved with 5 and 10 percent dimethyl sulfoxide alone give comparable hematopoietic reconstitution after transplantation.
    Akkök CA; Liseth K; Nesthus I; Løkeland T; Tefre K; Bruserud O; Abrahamsen JF
    Transfusion; 2008 May; 48(5):877-83. PubMed ID: 18298599
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Higher infused CD34+ hematopoietic stem cell dose correlates with earlier lymphocyte recovery and better clinical outcome after autologous stem cell transplantation in non-Hodgkin's lymphoma.
    Yoon DH; Sohn BS; Jang G; Kim EK; Kang BW; Kim C; Kim JE; Kim S; Lee DH; Lee JS; Park SJ; Park CJ; Huh J; Suh C
    Transfusion; 2009 Sep; 49(9):1890-900. PubMed ID: 19453991
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Etoposide 1.0 g/m2 or 1.5 g/m2 combined with granulocyte colony-stimulating factor for mobilization of peripheral blood stem cells in patients with malignancy: efficacy and toxicity.
    Li B; Yang JL; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang S; Zhang CG
    Cytotherapy; 2009; 11(3):362-71. PubMed ID: 19037766
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Large-volume-apheresis facilitates autologous transplantation of hematopoietic progenitors in poor mobilizer patients.
    Majado MJ; Minguela A; González-García C; Salido E; Blanquer M; Funes C; Insausti CL; García-Hernández AM; Moraleda JM; Morales A
    J Clin Apher; 2009; 24(1):12-7. PubMed ID: 19170164
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The impact of CD34+ cell dose on platelet engraftment in pediatric patients following unmanipulated haploidentical blood and marrow transplantation.
    Chang YJ; Xu LP; Liu DH; Liu KY; Han W; Chen YH; Wang Y; Chen H; Wang JZ; Zhang XH; Zhao XY; Huang XJ
    Pediatr Blood Cancer; 2009 Dec; 53(6):1100-6. PubMed ID: 19743519
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Beta-2-microglobulin level predicts outcome following autologous hematopoietic stem cell transplantation in patients with multiple myeloma.
    Stella-Holowiecka B; Czerw T; Holowiecka-Goral A; Giebel S; Wojnar J; Holowiecki J
    Transplant Proc; 2007 Nov; 39(9):2893-7. PubMed ID: 18022010
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Post-thaw viable CD34(+) cell count is a valuable predictor of haematopoietic stem cell engraftment in autologous peripheral blood stem cell transplantation.
    Lee S; Kim S; Kim H; Baek EJ; Jin H; Kim J; Kim HO
    Vox Sang; 2008 Feb; 94(2):146-52. PubMed ID: 18028260
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Failure to achieve a threshold dose of CD34+ CD110+ progenitor cells in the graft predicts delayed platelet engraftment after autologous stem cell transplantation.
    Sartor MM; Garvin F; Antonenas V; Bradstock KF; Gottlieb DJ
    Bone Marrow Transplant; 2007 Nov; 40(9):851-7. PubMed ID: 17704793
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Detection and quantification of functionally defined hematopoietic progenitor cells and tissue specific mRNA within the peripheral blood of myeloma patients after administration of granulocyte colony-stimulating factor and erythropoietin.
    Grassinger J; Mueller G; Hart C; Nilsson SK; Haylock DN; Andreesen R; Hennemann B
    Eur J Haematol; 2008 Jan; 80(1):20-30. PubMed ID: 18028434
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Peripheral blood stem cell mobilization with pegfilgrastim compared to filgrastim in children and young adults with malignancies.
    Fritsch P; Schwinger W; Schwantzer G; Lackner H; Sovinz P; Wendelin G; Benesch M; Sipurzynski S; Urban C
    Pediatr Blood Cancer; 2010 Jan; 54(1):134-7. PubMed ID: 19785023
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Predictive factors for a successful mobilization of peripheral blood CD34+ cells in multiple myeloma.
    Perea G; Sureda A; Martino R; Altés A; Martínez C; Cabezudo E; Amill B; Martín-Henao GA; González Y; Muñoz L; Peyret M; Brunet S; Sierra J
    Ann Hematol; 2001 Oct; 80(10):592-7. PubMed ID: 11732870
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Collection of peripheral blood progenitor cells: analysis of factors predicting the yields.
    Lee JL; Kim SB; Lee GW; Ryu MH; Kim EK; Kim S; Kim WK; Lee JS; Suh C
    Transfus Apher Sci; 2003 Aug; 29(1):29-37. PubMed ID: 12877890
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pegfilgrastim for peripheral CD34+ mobilization in patients with solid tumours.
    Willis F; Woll P; Theti D; Jamali H; Bacon P; Baker N; Pettengell R
    Bone Marrow Transplant; 2009 Jun; 43(12):927-34. PubMed ID: 19169289
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.